Form D · Biotechnology
Lila Biologics, Inc.
Seattle, WA · CIK 0001993436
Offering snapshot reported Sep 28, 2023 · SEC filing
- Reported sold
- $9.54M Offering amount: $10.6M
- Investors reported
- 18 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 14, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 28, 2023 | Initial | $9,537,323 | No comparison | 18 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-493247
Source: Form D, filed Sep 28, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| William Canestaro | Director |
| Sheila Gujrathi | Director |
| John Kraft, Ii | Director, Executive |
| Anindya Roy | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1616 Eastlake Ave East, Suite 208
Seattle, WA, 98102
Seattle, WA, 98102